The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With Diabetes
Open accessAbstract
Purpose: To evaluate the association between cumulative duration of metformin use after prostate cancer (PC) diagnosis and all-cause and PC-specific mortality among patients with diabetes. Patients and Methods: We used a population-based retrospective cohort design. Data were obtained from several Ontario health care administrative databases. Within a cohort of men older than age 66 years with incident diabetes who subsequently developed PC, we examined the effect of duration of antidiabetic medication exposure after PC diagnosis on all-cause and PC-specific mortality. Crude and adjusted hazard ratios (HRs) were calculated by using a time-varying Cox proportional hazard model to estimate effects. Results: The cohort consisted of 3,837 patients. Median age at diagnosis of PC was 75 years (interquartile range [IQR], 72 to 79 years). During a median follow-up of 4.64 years (IQR, 2.7 to 7.1 years), 1,343 (35%) died, and 291 patients (7.6%) died as a result of PC. Cumulative duration of metformin treatment after PC diagnosis was associated with a significant decreased risk of PC-specific and all-cause mortality in a dose-dependent fashion. Adjusted HR for PC-specific mortality was 0.76 (95% CI, 0.64 to 0.89) for each additional 6 months of metformin use. The association with all-cause mortality was also significant but declined over time from an HR of 0.76 in the first 6 months to 0.93 between 24 and 30 months. There was no relationship between cumulative use of other antidiabetic drugs and either outcome. Conclusion: Increased cumulative duration of metformin exposure after PC diagnosis was associated with decreases in both all-cause and PC-specific mortality among diabetic men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880
Metformin for the treatment of the polycystic ovary syndrome
Nestler, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0707092 · Cited by 313
Vazquez-Martin, A., Oliveras-Ferraros, C., & Menendez, J. A. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7499 · Cited by 250
Metformin and Other Biguanides in Oncology: Advancing the Research Agenda
Pollak, M. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0175 · Cited by 240
Longer Wait Times Increase Overall Mortality in Patients With Bladder Cancer
Kulkarni, G. S., Urbach, D. R., Austin, P. C., Fleshner, N. E., & Laupacis, A. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.06.041 · Cited by 123
Self-citation
Cited by
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
The Epidemiology of Prostate Cancer
Pernar, C. H., Ebot, E. M., Wilson, K. M., & Mucci, L. A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030361 · Cited by 773
Metformin in cancer prevention and therapy.
Kasznicki, J., Śliwińska, A., & Drzewoski, J. (2014) · PubMed · doi:10.3978/j.issn.2305-5839.2014.06.01 · Cited by 316
Vilar‐Gomez, E., Vuppalanchi, R., Desai, A. P., Gawrieh, S., Ghabril, M., Saxena, R., Cummings, O. W., & Chalasani, N. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15331 · Cited by 84
Metformin and prostate cancer mortality: A meta-analysis
Stopsack, K. H., Ziehr, D. R., Rider, J. R., & Giovannucci, E. L. (2016) · Cancer Causes & Control · doi:10.1007/s10552-015-0687-0 · Cited by 72
Metadata
- Authors
- Margel, D., Urbach, D. R., Lipscombe, L. L., Bell, C. M., Kulkarni, G., Austin, P. C., & Fleshner, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-09-01
- Volume
- 31
- Issue
- 25
- Pages
- 3069-3075
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2149179641
- Cited by
- 271
- References
- 7
- FWCI
- 17.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With Diabetes. https://app.cochat.ai/papers/10.1200/jco.2012.46.7043
- The paper
- Margel, D., Urbach, D. R., Lipscombe, L. L., Bell, C. M., Kulkarni, G., Austin, P. C., & Fleshner, N. (2013). Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With Diabetes. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.46.7043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.